Testing glofitamab plus chemo for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial adds glofitamab, a new targeted drug, to standard chemotherapy for people with untreated mantle cell lymphoma. The goal is to see if the combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mantle cell lymphoma that has not been treated before and is at a later stage
- You are between 18 and 75 years old
- You are in reasonably good health with adequate organ function
- You have not had prior treatment for mantle cell lymphoma
- You do not have active infections or serious heart, liver, or autoimmune conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
This trial tests if adding a new targeted drug called glofitamab to standard chemotherapy works better than chemo alone for people with Burkitt lymphoma or double hit lymphoma. It may be a good option if you are newly diagnosed or if your lymphoma has come back after treatment.
This trial tests a combination of two drugs, glofitamab and lenalidomide, for people with mantle cell lymphoma that has come back or not responded to treatment. It's for those with high-risk features, like a fast-growing lymphoma or resistance to previous therapies.
Hear when a new Ann Arbor Stage II Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.